Defunct Company
Total Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
433
NCT00358566
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Phase: Phase 3
Role: Lead Sponsor
Start: Jun 30, 2006
Completion: Aug 31, 2008
NCT00532974
A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)
Phase: Phase 1
Role: Collaborator
Start: Oct 31, 2006
Completion: Apr 30, 2008
NCT00444782
A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.
Phase: Phase 2
Start: Nov 30, 2006